The December 20, 2021, article by Leavey et al entitled “Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report” (J Clin Oncol 10.1200/JCO.21.00358) was published with errors.
In Table 3, “SNM” was included in the list of abbreviations. The correct abbreviation is “SMN.”
In Figure 3A, the age group for the first line of the risk table was listed as > 17 years. It should have been < 18 years.
In Figure 3B, the age group for the first line of the risk table was listed as < 17 years. It should have been < 18 years.
This has been corrected as of June 7, 2022. The authors apologize for the errors.